Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in Q4 revenues to $2.85 billion, beating the Wall Street consensus. The net income was reported at $358 million or $2.32 per share compared to the previous year’s $14.39 billion or $8.08 per share. […]
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in Q4 revenues to $2.85 billion, beating the Wall Street consensus. The net income was reported at $358 million or $2.32 per share compared to the previous year’s $14.39 billion or $8.08 per share. […]
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday.
The biotechnology giant reported a 22% decline in Q4 revenues to $2.85 billion, beating the Wall Street consensus.
The net income was reported at $358 million or $2.32 per share compared to the previous year’s $14.39 billion or $8.08 per share.
The stock was trading at $ $275 during the pre-market session on Wednesday showing a decline of 2%.
